Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Ulysses Diva et al.|The Lancet|2023Cited by 264
An eQTL Landscape of Kidney Tissue in Human Nephrotic SyndromeChristopher E. Gillies, Duncan B. Johnstone, Rosemary Putler et al.|The American Journal of Human Genetics|2018Cited by 184
JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosisJianling Tao, Richard Lafayette|Kidney International|2018Cited by 96